The Nicomide® Improvement in Clinical Outcomes Study (NICOS): Results of an 8-week trial

Cutis

Volumn 77, Issue 1 SUPPL., 2006, Pages 17-28

  Niren, Neil M ^a   Torok, Helen M ^b,c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Trillium Creek Dermatology and DermaSpa   (United States)

^c NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; NICOTINAMIDE; ZINC;

ACNE VULGARIS; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; DOSE RESPONSE; DRUG COMBINATION; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PATIENT SATISFACTION; PROSPECTIVE STUDY; ROSACEA; TREATMENT OUTCOME;

ACNE VULGARIS; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; NIACINAMIDE; PATIENT SATISFACTION; PROSPECTIVE STUDIES; ROSACEA; TREATMENT OUTCOME; ZINC;

EID: 31944441960     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Katsambas AD, Stefanaki C, Cunliffe WJ. Guidelines for treating acne. Clin Dermatol. 2004;22:439-444.
2. Berson DS, Chalker DK, Harper JC, et al. Current concepts in the treatment of acne: report from a clinical roundtable. Cutis. 2003;72(suppl 1):5-13.
3. Lee DJ, Van Dyke GS, Kim J. Update on pathogenesis and treatment of acne. Curr Opin Pediatr. 2003;15:405-410.
4. Gupta AK, Chaudhry MM. Rosacea and its management: an overview. J Eur Acad Dermatol Venereol. 2005;19: 273-285.
5. Rebora A. The management of rosacea. Am J Clin Dermatol. 2002;3:489-496.
6. Tan JK. Psychosocial impact of acne vulgaris: evaluating the evidence. Skin Therapy Lett. 2004;9:1-3, 9.
7. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol. 1998;139:846-850.
8. Blount BW, Pelletier AL. Rosacea: a common, yet commonly overlooked, condition. Am Fam Physician. 2002;66:435-440.
9. Harper JC. An update on the pathogenesis and management of acne vulgaris. J Am Acad Dermatol. 2004;51(suppl 1):S36-S38.
10. Cunliffe WJ. Acne vulgaris. In: Lebwohl M, Heymann WR, Berth-Jones J, et al, eds. Treatment of Skin Disease: Comprehensive Therapeutic Strategies. London, England: Mosby; 2002:6-13.
11. Haider A, Shaw JC. Treatment of acne vulgaris. JAMA. 2004;292:726-735.
12. Coates P, Vyakrnam S, Eady EA, et al. Prevalence of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distribution study. Br J Dermatol. 2002;146:840-848.
13. Shalita AR, Smith JG, Parish LC, et al. Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. Int J Dermatol. 1995;34: 434-437.
14. Griffiths CEM. Nicotinamide 4% gel for the treatment of inflammatory acne vulgaris. J Dermatol Treat. 1995;6(suppl 1):S8-S10.
15. Welten Y, Chartier S, Gibaud C, et al. Double-blind clinical assessment of the efficacy of a 4% nicotinamide gel (Exfoliac NC Gel) versus a 4% erythromycin gel in the treatment of moderate acne with a predominant inflammatory component. Nouv Dermatol. 2004;23:385-394.
16. Parsons WB. Studies of nicotinic acid use in hypercholesterolemia. Arch Intern Med. 1961;151:1424-1432.
17. Winter SL, Boyer JL. Hepatic toxicity from large does of vitamin B3 (nicotinamide). N Engl J Med. 1973;289:1180-1182.
18. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.
19. Haslam RH, Dalby JT, Rademaker AW. Effects of megavitamin therapy in children with attention deficit disorders. Pediatrics. 1984;74:103-110.
20. Lampeter EF, Klinghammer A, Scherbaum WA, et al. The Deutsche Nicotinamide Intervention Study: an attempt to prevent Type I diabetes. Diabetes. 1998;47:980-984.
21. Pozzilli P, Visalli N, Signore A, et al. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study). Diabetologia. 1995;38:848-852.
22. Chase HP, Butler-Simon N, Garg S, et al. A trial of nicotinamide in newly diagnosed patients with Type I (insulin dependent) diabetes mellitus. Diabetologia. 1990;34:444-446.
23. Mendola G, Casamitjana R, Gomis R. Effect of nicotinamide therapy upon B-cell function in newly-diagnosed Type I (insulin-dependent) diabetic patients. Diabetologia. 1989;32:160-162.
24. Vague P, Picq R, Bernal M, et al. Effect of nicotinamide on the residual insulin secretion of Type I (insulin-dependent) diabetic patients. Diabetologia. 1989;32:316-321.
25. Chaidemenos GC. Tetracycline and niacinamide in the treatment of blistering skin diseases. Clin Dermatol. 2001;19:781-785.
26. Reiche L, Wojnarowska F, Mallon E. Combination therapy with nicotinamide and tetracyclines for cicatricial pemphigoid: further support for its efficacy. Clin Exp Dermatol. 1998;23:254-257.
27. Hornschuh B, Hamm H, Wever S, et al. Treatment of 16 patients with bullous pemphigoid with oral tetracycline and niacinamide and topical clobetasol. J Am Acad Dermatol. 1997;36:101-103.
28. Kolbach DN, Remme JJ, Bos WH, et al. Bullous pemphigoid successfully controlled by tetracycline and nicotinamide. Br J Dermatol. 1995;133:88-90.
29. Poskitt L, Wojnarowska F. Treatment of cicatricial pemphigoid with tetracycline and nicotinamide. Clin Exp Dermatol. 1995;20:258-259.
30. Fivenson DP, Breneman DL, Rosen GB, et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol. 1994;130:753-758.
31. Chaffins ML, Collison D, Fivenson DP. Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases. J Am Acad Dermatol. 1993;28:998-1000.
32. Berk MA, Lorincz AL. The treatment of bullous pemphigoid with tetracycline and niacinamide. a preliminary report. Arch Dermatol. 1986;122:670-674.
33. Fivenson DP, Kimbrough TL. Lichen planus pemphigoides: combination therapy with tetracycline and nicotinamide. J Am Acad Dermatol. 1997;36:638-640.
34. Handfield-Jones S, Jones S, Peachey R. High dose nicotinamide in the treatment of necrobiosis lipoidica. Br J Dermatol. 1988;118:693-696.
35. Neumann R, Rappold E, Pohl-Markl H. Treatment of polymorphous light eruption with nicotinamide: a pilot study. Br J Dermatol. 1986;115:77-80.
36. Ma A, Medenica M. Response of generalized granuloma annulate to high-dose niacinamide. Arch Dermatol. 1983;119:836-839.
37. Jablonska S. Treatment of acne vulgaris and rosacea [letter]. Arch Dermatol. 1975;111:929.
38. Nicomide (nicotinamide, zinc oxide, cupric oxide, and folic acid) tablets [package insert]. Vernon Hills, Ill: Sirius Laboratories, Inc; 2003.
39. Fernandez-Obregon A, Davis MW. The BEST study: evaluating efficacy by selected demographic subsets. Cutis. 2003;71(suppl 2):18-26.
40. Westbrook JI. Patient satisfaction: methodological issues and research findings. Aust Health Rev. 1993;16:75-88.
41. Marks R. Acne and its management beyond the age of 35 years. Am J Clin Dermatol. 2004;5:459-462.
42. Dos S, Barbhuiya J, Jana S, et al. Comparative evaluation of clindamycin phosphate 1% and clindamycin phosphate 1% with nicotinamide gel 4% in the treatment of acne vulgaris. Indian J Dermatol Venereol Leprology. 2003;69:8-9.
43. Sardesai V, Kambli V. Comparison of efficacy of topical clindamycin and nicotinamide combination with plain clindamycin for the treatment of acne vulgaris and acne resistant to topical antibiotics. Indian J Dermatol Venereol Leprology. 2003;69:138-139.